Demographic data and baseline characteristics of study patients
| n | Bosentan cohort(N = 139) | n | Epoprostenol cohort(N = 346) | p value* | |
|---|---|---|---|---|---|
| mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; SD, standard deviation. | |||||
| *p values were determined using the Fisher’s exact test (sex) and the Student’s t test (all others). | |||||
| †For most bosentan treated patients, time from diagnosis and haemodynamic data were available only at the start of the placebo controlled study. | |||||
| Sex (M/F, %) | 139 | 20/80 | 346 | 26/74 | 0.240 |
| Age (years) | |||||
| Mean (SD) | 139 | 46 (16) | 341 | 41 (14) | <0.001 |
| Range | 13–80 | 10–75 | |||
| Time from diagnosis of PAH to start of treatment (months)* | |||||
| Mean (SD) | 138 | 32 (42) | 100 | 13 (21) | <0.001 |
| Range | 0.3–326 | 0–135 | |||
| Haemodynamics (mean (SD))† | |||||
| Cardiac index (l/min/m2) | 138 | 2.4 (0.8) | 317 | 2.0 (0.6) | <0.001 |
| PVR (Wood units) | 132 | 12 (6) | 207 | 18 (10) | <0.001 |
| mPAP (mm Hg) | 139 | 56 (15) | 333 | 66 (18) | <0.001 |
| mRAP (mm Hg) | 136 | 9 (5) | 330 | 11 (5) | <0.001 |
| Walk test (m) | |||||
| Mean (SD) | 139 | 351 (80) | 171 | 335 (106) | 0.136 |